Skip to content
Bored Studies
RecruitingPhase 2

A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO

EyeBiotech Ltd. · NCT07205887

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
160
US sites recruiting
55
Study start
September 12, 2025
Record last updated
October 20, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

EYE-RES-104 is a randomized, dose-masked study of intravitreal remigromig (EYE103) in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion (BRVO).

The study will consist of 4 patient cohorts, with participants in each cohort randomized (1:1) to either a low dose of remigromig via IVT or a high dose of remigromig via IVT. 40 participants will be enrolled in each cohort. Enrollment timing for each cohort will be sequenced into specific arms of the study at the Sponsor's discretion.

All participants in the study will receive a total of 3 injections of remigromig into the study eye, spaced at 4 weeks apart. All participants will return at designated time points following each injection for safety and efficacy assessments. The Week 12 Visit will serve as the end of study visit for all participants.

Being studied: Remigromig; Aflibercept 2.0 mg

Conditions: Neovascular Age-Related Macular Degeneration (NVAMD); Branch Retinal Vein Occlusion (BRVO)

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

Key General Inclusion Criteria

  • Be willing and able to understand the study procedures and the risks involved and provide written informed consent before the first study-related activity

Key Neovascular Age-related Macular Degeneration (NVAMD)-specific Inclusion Criteria

  • Be ≥ 50 years of age
  • Have treatment naive subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) or juxtafoveal/extrafoveal CNV with foveal involvement
  • For participants who are treatment naïve for NVAMD, the diagnosis must have been made within 21 days prior to the Day 1 study treatment

Key Incomplete Responder (IR) NVAMD-specific Inclusion Criteria

  • Be ≥ 50 years of age
  • Have subfoveal CNV secondary to AMD or juxtafoveal/extrafoveal CNV with foveal involvement at initial screening
  • For participants who are treatment experienced for NVAMD, the diagnosis must have been made within 90 days prior to the Screening Visit 2

Key Branch Retinal Vein Occlusion (BRVO)-specific Inclusion Criteria

  • Be diagnosed with BRVO in the study eye
  • Have a decrease in vision in the study eye determined by the Investigator to be primarily the result of BRVO
  • Be treatment naïve with vision loss in the study eye and have center-involving macular edema diagnosed within 9 months of Screening

Exclusion Criteria

Key General Exclusion Criteria

  • Pregnant or breastfeeding
  • History of cataract surgery and/or minimally invasive glaucoma surgery in the study eye within 90 days of Screening
  • Have had Yttrium-Aluminum Garnet (YAG) laser capsulotomy in the study eye within 90 days of Screening
  • Currently using drugs with known retinal toxicity (e.g., Hydroxychloroquine, pentosan polysulfate sodium, and amiodarone)

Key NVAMD-specific Exclusion Criteria

  • Have had previous thermal subfoveal laser therapy in the study eye
  • Have had previous photodynamic therapy with Visudyne in the study eye

Key BRVO-specific Exclusion Criteria

  • Have macular edema in the study eye considered to be secondary to a cause other than BRVO (eg, diabetic macular edema, NVAMD, Irvine-Gass syndrome)
  • Have active iris or angle neovascularization or neovascular glaucoma in the study eye

Recruiting US locations

  • Scottsdale, Arizona

    Scottsdale, AZ 85255

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • Scottsdale, AZ

    Scottsdale, AZ 85255

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • Glendale, California

    Glendale, CA 91204

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • Glendale, CA

    Glendale, CA 91204

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • Modesto, California

    Modesto, CA 95356

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • Mountain View, California

    Mountain View, CA 94040

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • Sacramento, CA

    Sacramento, CA 95825

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • Sactamento, California

    Sacramento, CA 95825

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • Sacramento, California

    Sacramento, CA 95841

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • Santa Ana, California

    Santa Ana, CA 92705

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • RSC Research LLC

    Denver, CO 80222

    Site contact: Study Coordinator · 720-443-2425

  • Fort Lauderdale, Florida

    Fort Lauderdale, FL 33308

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • Fort Lauderdale, FL

    Fort Lauderdale, FL 33308

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • Florida Retina Institute

    Jacksonville, FL 32216

    Site contact: Study Coordinator · 904-997-9202

  • Florida Retina Institute

    Orlando, FL 32806

    Site contact: Study Coordinator · 407-849-9621

  • Lemont, Illinois

    Lemont, IL 60439

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • Lemont, IL

    Lemont, IL 60439

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • Hagerstown, Maryland

    Hagerstown, MD 21740

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • Hagerstown, MD

    Hagerstown, MD 21740

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • Madison, Mississippi

    Madison, MS 39110

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • Madison, MS

    Madison, MS 39110

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • Bloomfield, New Jersey

    Bloomfield, NJ 07003

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • Bloomfield, NJ

    Bloomfield, NJ 07003

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • Long Island Vitreoretinal Consultants of NY

    Great Neck, NY 11021

    Site contact: Study Coordinator · 516-466-0390

  • Asheville, North Carolina

    Asheville, NC 28803

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • Cary, North Carolina

    Cary, NC 27511

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • North Carolina Retina Associates

    Greenville, NC 27834

    Site contact: Study Coordinator · 919-782-8038

  • Wake Forest, NC

    Wake Forest, NC 27587

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • Wake Forest, North Carolina

    Wake Forest, NC 27587

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • West Columbia, SC

    West Columbia, SC 29169

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • West Columbia, South Carolina

    West Columbia, SC 29169

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • Germantown, Tennessee

    Germantown, TN 38138

    Site contact: Charles Miller, MD PhD · ClinicalInquiries@eyebiotech.com

  • Knoxville, Tennessee

    Knoxville, TN 37922

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • Nashville, Tennessee

    Nashville, TN 37203

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • Nashville, TN

    Nashville, TN 37203

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • Abilene, Texas

    Abilene, TX 79606

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • Amarillo, Texas

    Amarillo, TX 79106

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • Austin, Texas

    Austin, TX 78705

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • Austin, TX

    Austin, TX 78705

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • Bellaire, Texas

    Bellaire, TX 77401

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • Bellaire, TX

    Bellaire, TX 77401

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • Burleson, Texas

    Burleson, TX 76028

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • Dallas, Texas

    Dallas, TX 75231

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • Dallas, TX

    Dallas, TX 75231

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • Plano, Texas

    Plano, TX 75075

    Site contact: Charles Miller, MD PhD · ClinicalInquiries@eyebiotech.com

  • Round Rock, TX

    Round Rock, TX 78681

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • Round Rock, Texas

    Round Rock, TX 78781

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • San Antonio, Texas

    San Antonio, TX 78240

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • San Antonio, TX

    San Antonio, TX 78240

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • San Marcos, Texas

    San Marcos, TX 78666

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • The Woodlands, Texas

    The Woodlands, TX 77384

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • The Woodlands, TX

    The Woodlands, TX 77384

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • Willow Park, Texas

    Willow Park, TX 76087

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • West Jordan, Utah

    West Jordan, UT 84088

    Site contact: Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com

  • Retina Consultants, PLLC

    Charleston, WV 25301

    Site contact: Study Coordinator · 304-346-4400

Study contacts (from the official record)

  • Charles Miller, MD PhD · 212-914-0127 · ClinicalInquiries@eyebiotech.com
A Dose-masked Study of Intravitreal Remigromig (EYE103) in… (NCT07205887) | Bored Studies